Brief: Orgenesis Enters Second Phase Of Collaboration With Hospital Infantil Universitario Niño Jesús In Madrid
11/03/2021 12:08
March 11 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ENTERS SECOND PHASE OF COLLABORATION WITH
HOSPITAL
INFANTIL UNIVERSITARIO NIÑO JESÚS IN MADRID WITH EXCLUSIVE
LICENSE TO COMMERCIALIZE CELYVIR SOLID TUMOR THERAPY
Source text for Eikon: ID:nGNX5Lz2vD
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules